Hepatoprotective Efficacy of Selegiline: Molecular Insight

Liver fibrosis is a form of wound healing that develops in response to persistent liver injury brought on by viruses, poisons, and medicines that are harmful to the liver. Inflammation is a hallmark of the condition, which is then followed by the formation of scar tissue via the deposition of extracellular matrix proteins. Hepatitis C virus (HCV) entrance has been linked to the host cofactor ephrin receptor A2 (EphA2). Selegiline hydrochloride is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as l-deprenyl. Selegiline (deprenyl) is a selective inhibitor of cerebral monoamine oxidase type B at the dosage (10 mg/day) used in patients with Parkinson's disease. Through this activity, the drug increases nigrostriatal dopamine levels, and may protect neurons against damage by free radicals and possibly exogenous neurotoxins.The exact mechanism of action for the hepatoprotective action of Selegiline was still not revealed. With intent to propose the most probable mechanism of action of Selegiline the docking based computational analysis has been performed against the hepatoprotective drug targets like PPARα enzyme.